Cargando…

Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis

BACKGROUND: Hepatitis C diagnosis could be a gateway to behavioral change and subsequent decline in transmission among people who inject drugs (PWIDs). We assessed the association between the social determinants of PWID, their risk behaviors and hepatitis C testing. METHODS: We searched for studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Karimi, Salah Eddin, Bayani, Azadeh, Higgs, Peter, Bayat, Amir-Hossein, Hemmat, Morteza, Ahounbar, Elahe, Armoon, Bahram, Fakhri, Yadolah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445934/
https://www.ncbi.nlm.nih.gov/pubmed/32831107
http://dx.doi.org/10.1186/s13011-020-00306-1
_version_ 1783574081162969088
author Karimi, Salah Eddin
Bayani, Azadeh
Higgs, Peter
Bayat, Amir-Hossein
Hemmat, Morteza
Ahounbar, Elahe
Armoon, Bahram
Fakhri, Yadolah
author_facet Karimi, Salah Eddin
Bayani, Azadeh
Higgs, Peter
Bayat, Amir-Hossein
Hemmat, Morteza
Ahounbar, Elahe
Armoon, Bahram
Fakhri, Yadolah
author_sort Karimi, Salah Eddin
collection PubMed
description BACKGROUND: Hepatitis C diagnosis could be a gateway to behavioral change and subsequent decline in transmission among people who inject drugs (PWIDs). We assessed the association between the social determinants of PWID, their risk behaviors and hepatitis C testing. METHODS: We searched for studies in English published before May 1, 2020, on PubMed, Scopus, Cochrane, and Web of Science to identify primary studies on the factors associated with hepatitis C virus (HCV) testing among PWID. After reviewing for study duplicates, the full-text of selected articles were assessed for eligibility using Population, Intervention, Comparator, Outcomes (PICO) criteria. i) population: individuals who report injecting drugs; ii) intervention: HCV testing in the past year; iii) comparator: PWIDs who did not have an HCV test; iv) outcome: HCV testing among PWIDs and v) study type: cross-sectional, cohort, and case-control studies. Two independent reviewers (author BA and AB) chose the references in a two-phased monitoring process. The authors gathered data from selected papers, including the surname of the first author, publication date, participant demographic data (age, sex, and level of education) and other characteristics like previous HCV testing, past treatment attempts, duration of injecting drug use and condomless sex. We used fixed and random-effects meta-analysis models to estimate the pooled prevalence, pooled odds ratio (OR), and 95% confidence intervals. The data were analyzed using Stata 12.0 software. RESULTS: After a detailed assessment of over 12,000 articles, a total of 16 studies containing 38,952 participants met the eligibility criteria. Our findings showed a pooled prevalence rate of 61.01% (95% CI, 34.65–84.32%) for recent HCV testing among PWIDs. Being female (OR = 1.69, 95%CI = 1.13, 2.26), aged > 30 years, (OR = 2.61, 95%CI = 1.66–3.56) having past treatment attempt (OR = 2.24, 95%CI = 1.80–2.68), and reporting a previous test (OR = 2.03, 95%CI = 1.23–2.82). were significantly associated with having a recent HCV test.,,. Finding of present study was that unprotected sex had a negative association with HCV testing. Those PWIDs who had unprotected sex were 0.56 times less likely to have completed HCV testing during last year (OR = 0.56, 95%CI = 0.33–0.78). CONCLUSION: Prevention programs that address age > 30 years, being female, past treatment attempt, previous testing of safe sexual practices, are strongly recommended to prioritize HCV risk reduction strategies.
format Online
Article
Text
id pubmed-7445934
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74459342020-08-26 Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis Karimi, Salah Eddin Bayani, Azadeh Higgs, Peter Bayat, Amir-Hossein Hemmat, Morteza Ahounbar, Elahe Armoon, Bahram Fakhri, Yadolah Subst Abuse Treat Prev Policy Review BACKGROUND: Hepatitis C diagnosis could be a gateway to behavioral change and subsequent decline in transmission among people who inject drugs (PWIDs). We assessed the association between the social determinants of PWID, their risk behaviors and hepatitis C testing. METHODS: We searched for studies in English published before May 1, 2020, on PubMed, Scopus, Cochrane, and Web of Science to identify primary studies on the factors associated with hepatitis C virus (HCV) testing among PWID. After reviewing for study duplicates, the full-text of selected articles were assessed for eligibility using Population, Intervention, Comparator, Outcomes (PICO) criteria. i) population: individuals who report injecting drugs; ii) intervention: HCV testing in the past year; iii) comparator: PWIDs who did not have an HCV test; iv) outcome: HCV testing among PWIDs and v) study type: cross-sectional, cohort, and case-control studies. Two independent reviewers (author BA and AB) chose the references in a two-phased monitoring process. The authors gathered data from selected papers, including the surname of the first author, publication date, participant demographic data (age, sex, and level of education) and other characteristics like previous HCV testing, past treatment attempts, duration of injecting drug use and condomless sex. We used fixed and random-effects meta-analysis models to estimate the pooled prevalence, pooled odds ratio (OR), and 95% confidence intervals. The data were analyzed using Stata 12.0 software. RESULTS: After a detailed assessment of over 12,000 articles, a total of 16 studies containing 38,952 participants met the eligibility criteria. Our findings showed a pooled prevalence rate of 61.01% (95% CI, 34.65–84.32%) for recent HCV testing among PWIDs. Being female (OR = 1.69, 95%CI = 1.13, 2.26), aged > 30 years, (OR = 2.61, 95%CI = 1.66–3.56) having past treatment attempt (OR = 2.24, 95%CI = 1.80–2.68), and reporting a previous test (OR = 2.03, 95%CI = 1.23–2.82). were significantly associated with having a recent HCV test.,,. Finding of present study was that unprotected sex had a negative association with HCV testing. Those PWIDs who had unprotected sex were 0.56 times less likely to have completed HCV testing during last year (OR = 0.56, 95%CI = 0.33–0.78). CONCLUSION: Prevention programs that address age > 30 years, being female, past treatment attempt, previous testing of safe sexual practices, are strongly recommended to prioritize HCV risk reduction strategies. BioMed Central 2020-08-24 /pmc/articles/PMC7445934/ /pubmed/32831107 http://dx.doi.org/10.1186/s13011-020-00306-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Karimi, Salah Eddin
Bayani, Azadeh
Higgs, Peter
Bayat, Amir-Hossein
Hemmat, Morteza
Ahounbar, Elahe
Armoon, Bahram
Fakhri, Yadolah
Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis
title Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis
title_full Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis
title_fullStr Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis
title_full_unstemmed Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis
title_short Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis
title_sort prevalence and high risk behaviours associated with hcv testing among people who inject drugs: a systematic review and meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445934/
https://www.ncbi.nlm.nih.gov/pubmed/32831107
http://dx.doi.org/10.1186/s13011-020-00306-1
work_keys_str_mv AT karimisalaheddin prevalenceandhighriskbehavioursassociatedwithhcvtestingamongpeoplewhoinjectdrugsasystematicreviewandmetaanalysis
AT bayaniazadeh prevalenceandhighriskbehavioursassociatedwithhcvtestingamongpeoplewhoinjectdrugsasystematicreviewandmetaanalysis
AT higgspeter prevalenceandhighriskbehavioursassociatedwithhcvtestingamongpeoplewhoinjectdrugsasystematicreviewandmetaanalysis
AT bayatamirhossein prevalenceandhighriskbehavioursassociatedwithhcvtestingamongpeoplewhoinjectdrugsasystematicreviewandmetaanalysis
AT hemmatmorteza prevalenceandhighriskbehavioursassociatedwithhcvtestingamongpeoplewhoinjectdrugsasystematicreviewandmetaanalysis
AT ahounbarelahe prevalenceandhighriskbehavioursassociatedwithhcvtestingamongpeoplewhoinjectdrugsasystematicreviewandmetaanalysis
AT armoonbahram prevalenceandhighriskbehavioursassociatedwithhcvtestingamongpeoplewhoinjectdrugsasystematicreviewandmetaanalysis
AT fakhriyadolah prevalenceandhighriskbehavioursassociatedwithhcvtestingamongpeoplewhoinjectdrugsasystematicreviewandmetaanalysis